Grantham, Mayo, Van Otterloo & Co (GMO)’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-85,050	Closed	-$4.08M	–	868
2020 Q1	$4.08M	Buy	+85,050	New	+$3.96M	0.03%	272

Other funds holding RARX

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s RARX Position: Q2 2020 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 85,050 shares — an estimated $4.08M sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in RARX in Q1 2020 and held it in 1 quarter. The position peaked at $4.08M in Q1 2020. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Grantham, Mayo, Van Otterloo & Co (GMO) sold 85,050 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $4.08M.
Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q1 2020 and held it in 1 quarter.
Grantham, Mayo, Van Otterloo & Co (GMO)'s Ra Pharmaceuticals, Inc. Common Stock position peaked at $4.08M in Q1 2020.
1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q2 2020, filed 13 Aug 2020.